1197 related articles for article (PubMed ID: 31796105)
1. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
2. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Guo L; Wu Z
Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
[TBL] [Abstract][Full Text] [Related]
3. FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Peng WX; Han X; Zhang CL; Ge L; Du FY; Jin J; Gong AH
Cell Biol Toxicol; 2017 Dec; 33(6):527-537. PubMed ID: 28185110
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
[TBL] [Abstract][Full Text] [Related]
7. A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Liu T; Hu J; Han B; Tan S; Jia W; Xin Y
Cell Death Dis; 2021 Oct; 12(11):952. PubMed ID: 34657141
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Ni Q; Fan Y; Zhang X; Fan H; Li Y
J Ethnopharmacol; 2019 Oct; 242():111699. PubMed ID: 31005632
[TBL] [Abstract][Full Text] [Related]
9. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
10. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
11. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Reich TR; Schwarzenbach C; Vilar JB; Unger S; Mühlhäusler F; Nikolova T; Poplawski A; Baymaz HI; Beli P; Christmann M; Tomicic MT
Cell Mol Life Sci; 2021 Jul; 78(14):5587-5604. PubMed ID: 34100981
[TBL] [Abstract][Full Text] [Related]
12. FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
He C; Lu S; Wang XZ; Wang CC; Wang L; Liang SP; Luo TF; Wang ZC; Piao MH; Chi GF; Ge PF
Acta Pharmacol Sin; 2021 Aug; 42(8):1324-1337. PubMed ID: 33879840
[TBL] [Abstract][Full Text] [Related]
13. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
14. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
15. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
16. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
17. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
19. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Liu N; Hu G; Wang H; Li Z; Guo Z
J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Zhang X; Ni Q; Wang Y; Fan H; Li Y
Biol Pharm Bull; 2018 Aug; 41(8):1194-1202. PubMed ID: 29848900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]